El interés en corto de Integra Lifesciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Integra Lifesciences. Los datos de interés en corto se actualizan cada dos semanas.

Integra Lifesciences (NASDAQ:IART) Bolsa, Informe de interés en corto

Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences Holdings Corp

INTEGRA LIFESCIENCES HOLDINGS ORD

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $26 to $21.

News

Price Target

Analyst Ratings

IART

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $21

B of A Securities analyst Craig Bijou maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Underperform and lowers the price target from $26 to $18.

B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18

BTIG analyst Ryan Zimmerman upgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Sell to Neutral.

Upgrades

BTIG Upgrades Integra Lifesciences to Neutral

In the last three months, 10 analysts have published ratings on Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Integra Lifesciences and provided 12-month price targets. The average target is $25.1, accompanied by a high estimate of $35.00 and a low estimate of $16.00. Experiencing a 7.41% decline, the current average is now lower than the previous average price target of $27.11. 
<img src="https://www.benzinga.com/files/images/story/2024/1727805731_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Integra Lifesciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Sell</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Integra Lifesciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Integra Lifesciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integra Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Integra Lifesciences</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>Integra Lifesciences: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Integra Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.68%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Integra Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Integra Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.79%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.3%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.31, Integra Lifesciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 10 Analyst Insights On Integra Lifesciences

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $20 to $16.

Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $16

BTIG analyst Ryan Zimmerman maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $22 to $20.

BTIG Maintains Sell on Integra Lifesciences, Lowers Price Target to $20

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.88, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 6.86% decline, the current average is now lower than the previous average price target of $28.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1724342454_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Integra Lifesciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Sell</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Integra Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Integra Lifesciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integra Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Integra Lifesciences</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>Unraveling the Financial Story of Integra Lifesciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Integra Lifesciences's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.68%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Integra Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of -2.97%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Integra Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of -0.79%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.3%, the company showcases effective utilization of assets.
Debt Management: Integra Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 1.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $23 to $20.

Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $20

Integra LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported upbeat second-quarter earnings and lowered its FY24 guidance below <a href="https://www.benzinga.com/quote/IART/earnings">estimates on Monday</a>.
Integra Lifesciences posted adjusted earnings of 63 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $418.175 million topping expectations of $413.154 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
&#8220;Our second quarter financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams,&#8221; said Jan De Witte, Integra LifeSciences&#8217; president and chief executive officer. &#8220;Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, reliability and resilience of our manufacturing operations and supply chain. The reduction in our full-year guidance reflects an updated view of our operational challenges and critical investments in our compliance improvement program that will allow our supply to meet our strong commercial demand strength over time.&#8221;&nbsp;&nbsp;
Integra LifeSciences said it sees FY24 revenue of $1.609 billion to $1.629 billion versus prior forecast of $1.672 billion to $1.687 billion. The company now sees adjusted earnings of $2.41 to $2.57 per share, versus previous outlook of $3.01 to $3.11 per share.
Integra LifeSciences shares fell 0.7% to trade at $25.25 on Tuesday.
These analysts made changes to their price targets on Integra LifeSciences following the announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad9359b85e930001f97190/joanne-wuensch">Citigroup analyst Joanne Wuensch</a> downgraded Integra Lifesciences from Neutral to Sell and lowered the price target from $30 to $23.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ee202d0bd99100012327b8/richard-newitter">Truist Securities analyst Richard Newitter</a> maintained the stock with a Hold, while cutting the price target from $32 to $26.</li>
<li><a href="https://drupal-cloudfront.benzinga.com/topic/david-turkaly">JMP Securities analyst David Turkaly</a> maintained Integra Lifesciences with a Market Outperform, while slashing the price target from $40 to $35.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40039797/top-3-health-care-stocks-you-may-want-to-dump-this-quarter">Top 3 Health Care Stocks You May Want To Dump This Quarter</a></li>
</ul>

Earnings

Markets

Trading Ideas

Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Market Outperform and lowers the price target from $40 to $35.

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $32 to $26.

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $26

WIIM

Integra Lifesciences shares are trading lower after Citigroup and BTIG both downgraded the stock from Neutral to Sell. The company recently lowered its FY24 guidance.

Citigroup analyst Joanne Wuensch downgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Neutral to Sell and lowers the price target from $30 to $23.

Downgrades

Citigroup Downgrades Integra Lifesciences to Sell, Lowers Price Target to $23

BTIG analyst Ryan Zimmerman downgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Neutral to Sell and announces $22 price target.

BTIG Downgrades Integra Lifesciences to Sell, Announces $22 Price Target

Shares of Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) fell sharply during Monday's session after the company reported <a href="https://www.benzinga.com/quote/BMRC/earnings">worse-than-expected quarterly earnings.</a>
Bank of Marin reported quarterly earnings of 6 cents per share which missed the analyst consensus estimate of 18 cents per share. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Bank of Marin Bancorp shares dipped 10.8% to $19.92 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares climbed 128% to $2.8535.</li>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares climbed 117.8% to $0.9039 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) gained 61.6% to $4.75 after jumping around 56% on Friday.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) jumped 38% to $0.2644 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 37.8% to $0.6232 after gaining 11% on Friday.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) gained 34.4% to $12.25.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) jumped 26.8% to $14.76.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) jumped 24.2% to $0.4366.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) rose 23.5% to $2.9860.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) jumped 22.5% to $0.7936 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) gained 21.3% to $2.8862. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and announced a price target of $17.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares gained 19.8% to $4.1246 after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 19.3% to $0.5021. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) climbed 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.</li>
<li>PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) rose 18.4% to $4.19.</li>
<li>Cepton, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) jumped 18.4% to $2.9950 after the company announced it will be acquired by Koito for $3.17 per share in cash.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 17.2% to $2.25 after reporting preliminary second quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 16.1% to $15.35.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) jumped 13.7% to $79.76 after the company reported better-than-expected second quarter financial results.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) rose 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) gained 9.5% to $5.09.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 6.4% to $7.18. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) fell 34% to $1.5650 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dipped 31.4% to $14.55 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 28.6% to $0.1830 after gaining 6% on Friday.</li>
<li>Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) fell 26.4% to $14.90 following downbeat quarterly results.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) dipped 24.4% to $2.23. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 19.6% to $0.1536 after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) declined 18.5% to $8.84.</li>
<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) fell 17.5% to $0.2544.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 17% to $1.5243.</li>
<li>Integra Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#NYSE">ITRG</a>) fell 16.6% to $0.8999. Integra Resources and Florida Canyon Gold entered into a definitive arrangement agreement, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 16.6% to $3.3616. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 13.9% to $27.05 after the company lowered its FY24 guidance below estimates.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 12.8% to $14.01.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) fell 10.5% to $9.60.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) declined 10% to $7.24. Truist Securities analyst Jordan Levy maintained Sunnova Energy Intl with a Buy and raised the price target from $9 to $10.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $6.85. Mesoblast, last week, announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 6.3% to $139.61 after HSBC downgraded the stock from Hold to Reduce.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) fell 6.3% to $37.53.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40011559/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Intraday Update

Movers

AVXL

BMRC

CERO

CGTX

COMM

COUR

CPTN

CTRI

ITRG

LGVN

LIPO

LUXH

MESO

NIPG

NISN

NLSP

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

VERO

VTVT

VTYX

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

Integra LifeSciences shares are trading lower after the company lowered its FY24 guidance below estimates.

U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday.
Shares of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) fell in today&#8217;s pre-market trading after the company was ordered to pay $495 million in damages in its baby formula case.
Abbott shares lost 6.6% to $98.29 in pre-market trading
<ul>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 20.5% to $25.00 in pre-market trading after the company reported second-quarter results and lowered its FY24 outlook.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) fell 13.8% to $16.26 in pre-market trading as the company announced topline data from pivotal Phase 3 BROOKLYN clinical trial evaluating Obicetrapib in patients wth Heterozygous Familial Hypercholesterolemia.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) shares declined 8.8% to $9.41 in pre-market trading.</li>
<li>GeoPark Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) shares fell 6.5% to $9.52 in pre-market trading. GeoPark, last week, issued second quarter operational update.</li>
<li>Immutep Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) shares dipped 6.5% to $2.03 in pre-market trading. Immutep, last week, announced successful meeting with the FDA on Phase III design in non-small cell lung cancer.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) shares fell 5.4% to $8.75 in pre-market trading.</li>
<li>ICL Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) shares fell 4.1% to $4.43 in pre-market trading. ICL will release second quarter results before the opening of the TASE market on Wednesday, Aug. 14.</li>
<li>PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) slipped 3% to $126.84 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here">Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here&#8217;</a></li>
</ul>

Pre-Market Outlook

EZPW

GPRK

IMMP

IOVA

NAMS

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

2024&nbsp;Outlook
For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to&nbsp;$1.609&nbsp;to&nbsp;$1.629 billion&nbsp;and&nbsp;$2.41&nbsp;to&nbsp;$2.57, respectively. The revenue range represents reported growth of&nbsp;4.4%&nbsp;to&nbsp;5.7%, with organic growth of &ndash;1.0%&nbsp;to&nbsp;0.3%, reflecting&nbsp;third quarter&nbsp;quality and labeling compliance shipping holds and significant second half investments in quality and compliance improvement.

Guidance

Integra LifeSciences Expects FY24 Revenue of $1.609B-$1.629B (Prior $1.672B-$1.687B) Vs $1.676B Est, Adj EPS of $2.41-$2.57 (Prior $3.01-$3.11) Vs $3.04 Est

2024&nbsp;Outlook
For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to&nbsp;$1.609&nbsp;to&nbsp;$1.629 billion&nbsp;and&nbsp;$2.41&nbsp;to&nbsp;$2.57, respectively. The revenue range represents reported growth of&nbsp;4.4%&nbsp;to&nbsp;5.7%, with organic growth of &ndash;1.0%&nbsp;to&nbsp;0.3%, reflecting&nbsp;third quarter&nbsp;quality and labeling compliance shipping holds and significant second half investments in quality and compliance improvement.
For the&nbsp;third quarter&nbsp;2024, the Company expects reported revenues in the range of&nbsp;$372 million&nbsp;to&nbsp;$382 million, representing reported growth of&nbsp;-2.6%&nbsp;to&nbsp;0.0%&nbsp;and organic growth of&nbsp;-9.4%&nbsp;to &ndash;6.7%. The Company expects adjusted EPS in a range of&nbsp;$0.36&nbsp;to&nbsp;$0.44.
The Company&#39;s organic sales growth&nbsp;guidance&nbsp;for the&nbsp;third quarter&nbsp;and the full-year excludes acquisitions and divestitures, as well as the effects of foreign currency.

Integra LifeSciences Expects Q3 Revenue Of $372M-$382M Vs $432.11M Est, Adj EPS Of $0.36-$0.44 Vs $0.85 Est

Earnings Beats

Integra Lifesciences Q2 2024 Adj EPS $0.63 Beats $0.62 Estimate, Sales $418.175M Beat $413.154M Estimate

Truist Financial analyst Richard Newitter maintained a Hold rating on Integra Lifesciences (IART – Research Report) today and set a price target of...

Truist Financial Reaffirms Their Hold Rating on Integra Lifesciences (IART)

Morgan Stanley analyst Drew Ranieri maintained a Sell rating on Integra Lifesciences (IART – Research Report) today and set a price target of $25.0...

Integra Lifesciences (IART) Receives a Sell from Morgan Stanley

Integra LifeSciences downgraded at Citi, BTIG following guidance changes

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of July 29 through Aug. 2.

Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 3

BTIG analyst Ryan Zimmerman maintained a Sell rating on Integra Lifesciences (IART – Research Report) today and set a price target of $20.00. The c...

BTIG Sticks to Their Sell Rating for Integra Lifesciences (IART)

Analyst Vik Chopra from Wells Fargo maintained a Hold rating on Integra Lifesciences (IART – Research Report) and keeping the price target at $25.0...

Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact with a Long-Term Recovery Outlook

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

Wall Street Breakfast: The Week Ahead

The Top Five short crowded stocks in each U.S. sector

Craig Bijou, an analyst from Bank of America Securities, reiterated the Sell rating on Integra Lifesciences (IART – Research Report). The associate...

Integra Lifesciences Sell Rating: Overly Ambitious Targets Amid Persistent Operational Challenges

AERG

AFRM

ALXO

APLE

ASIX

AVNW

AZUL

BEPC

BIRD

BIRK

BMBL

BMRN

BRZE

CABO

CBRL

CERT

CMTL

COST

CVNA

ECVT

ETON

EVTC

GOOGL

GRDN

HUBS

IMRX

INST

INTC

INTU

LGCY

LUNR

MNTK

MPAA

NAPA

NBIX

NEWT

NTST

NVAX

NXDT

NXST

PDCO

PYPL

RDDT

REXR

SFIX

SIRI

TROW

TURB

ULCC

VERV

VSTO

VTLE

ZETA

Press Releases

Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024

Alltrna Announces Updates to Its Board of Directors

INTEGRA LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Integra LifeSciences Holdings Corporation - IART

Integra LifeSciences Reports Second Quarter 2024 Financial Results

Integra LifeSciences Continues to Make Progress on Its ESG Strategy

Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference

Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference

Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024

Comments

Integra Lifesciences

Interés en corto

Integra Lifesciences (NASDAQ:IART) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL